From the Journals

AML leads percent gains in 5-year survival among leukemias


 

Over the 60-year span from the early 1950s to 2013, the 5-year survival rate for all leukemias increased by 500%, according to data from the Surveillance, Epidemiology, and End Results Program.

For 2008-2013, the 5-year relative survival rate for all leukemias was 60.1%, compared with 10% during 1950-1954, said Ali H. Mokdad, PhD, and his associates at the Institute for Health Metrics and Evaluation at the University of Washington, Seattle (JAMA 2017;317[4]:388-406).

Five-year survival rate for all leukenia up 500%
Data for the various types of leukemia were not available for 1950-1954, so the changes in the 5-year survival for those included in the study are calculated from 1973-1977 to 2008-2013. Chronic lymphoid leukemia (CLL) had the highest survival rate at both time periods and the smallest increase at 23%. Acute lymphoid leukemia (ALL) had a 74% increase in survival, chronic myeloid leukemia (CML) had a 215% increase in survival, and acute myeloid leukemia (AML) had the largest increase at 342%, the investigators reported.

Recommended Reading

CAR T-cell therapy eyed for CLL patients with residual disease
MDedge Hematology and Oncology
CLL: Genetic aberrations predict poor treatment response in elderly
MDedge Hematology and Oncology
Survival in CLL predicted by minimum residual disease
MDedge Hematology and Oncology
CD49d trumps novel recurrent mutations for predicting overall survival in CLL
MDedge Hematology and Oncology
Minimal residual disease status predicts 10-year survival in CLL
MDedge Hematology and Oncology
Targeted therapies predicted to blow out costs for CLL
MDedge Hematology and Oncology
Idelalisib held unlikely to become frontline therapy for CLL
MDedge Hematology and Oncology
Lenalidomide improves PFS after 1st and 2nd line CLL therapy
MDedge Hematology and Oncology
Ibrutinib continues to wow in CLL/SLL
MDedge Hematology and Oncology
Lenalidomide maintenance extended progression-free survival in high-risk CLL
MDedge Hematology and Oncology